Skip to content

Acupuncture Combined with Topical Therapy for Hormone-Dependent Mild to Moderate Psoriasis

Efficacy Observation of Acupuncture Combined with Conventional Topical Medications for Hormone-Dependent Mild to Moderate Psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099718
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Sham acupuncture plus conventional medication group:Sham acupuncture + Conventional topical medication
Acupuncture plus conventional medication group:Acupuncture + Conventional topical medication

Sponsors

Chengdu Pidu District Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18-65 years ; 2. Diagnosed with psoriasis according to the clinical diagnostic criteria of the 'Chinese Guidelines for Diagnosis and Treatment of Psoriasis' with disease duration =6 months; 3. Baseline PASI score of 3-10; 4. Baseline BSA of 3-10% 5. Signed informed consent form; 6. Meeting at least one of the following conditions: i. Previous attempts to discontinue corticosteroids resulted in PASI rebound >=50% within 2 weeks ii. Requires topical corticosteroid application >=3 times per week to maintain disease stability Patients must meet all 6 criteria above to be included in the study.

Exclusion criteria

Exclusion criteria: 1.Generalized pustular psoriasis or erythrodermic psoriasis; 2.Concurrent severe gastrointestinal diseases hepatic or renal dysfunction immunodeficiency disorders or severe psychiatric conditions; 3.Pregnant or breastfeeding women; 4.History of allergy to calcipotriol or corticosteroids; 5.Participation in other clinical trials within the past month; 6.Systemic use of immunosuppressants or biologics within the past 4 weeks Subjects meeting any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
PASI 50 response rate;

Secondary

MeasureTime frame
Relapse Rate;Duration of Medication Effectiveness;PASI 75 Response Rate;Physician/Patient Global Assessment;Change in Dermatology Life Quality Index;Days to PASI =2;Pittsburgh Sleep Quality Index Score;Depression (PHQ-9) Scale Scores;Anxiety;Cumulative Dosage of Topical Medications;Percentage change in BSA;

Countries

China

Contacts

Public ContactPeng Changen

Chengdu Pidu District Hospital of Traditional Chinese Medicine

Mikepen@qq.com+86 136 0819 7127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026